AU2001233757A1 - Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases - Google Patents

Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases

Info

Publication number
AU2001233757A1
AU2001233757A1 AU2001233757A AU3375701A AU2001233757A1 AU 2001233757 A1 AU2001233757 A1 AU 2001233757A1 AU 2001233757 A AU2001233757 A AU 2001233757A AU 3375701 A AU3375701 A AU 3375701A AU 2001233757 A1 AU2001233757 A1 AU 2001233757A1
Authority
AU
Australia
Prior art keywords
prophylaxis
treatment
pulmonary
novel use
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233757A
Inventor
Dietrich Hafner
Christoph Karl
Andreas Keller
Frank Rathgeb
Peter Schaffer
Wilhelm Wurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of AU2001233757A1 publication Critical patent/AU2001233757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001233757A 2000-02-11 2001-02-10 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases Abandoned AU2001233757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00102858 2000-02-11
EP00102858 2000-02-11
PCT/EP2001/001485 WO2001058423A1 (en) 2000-02-11 2001-02-10 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases

Publications (1)

Publication Number Publication Date
AU2001233757A1 true AU2001233757A1 (en) 2001-08-20

Family

ID=8167832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233757A Abandoned AU2001233757A1 (en) 2000-02-11 2001-02-10 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases

Country Status (6)

Country Link
US (1) US20030091509A1 (en)
EP (1) EP1259222A1 (en)
JP (1) JP2003522138A (en)
AU (1) AU2001233757A1 (en)
CA (1) CA2399944A1 (en)
WO (1) WO2001058423A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002255181A1 (en) * 2001-05-21 2002-12-03 Britannia Pharmaceuticals Limited Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs
GB0117911D0 (en) * 2001-07-23 2001-09-12 Britannia Pharmaceuticals Ltd Pulmonary humectant
CA2450770A1 (en) * 2001-08-01 2003-02-13 Altana Pharma Ag Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome
EP1435994B1 (en) * 2001-10-11 2010-05-19 Nycomed GmbH Novel use of pulmonary surfactant
TW200410923A (en) * 2002-10-17 2004-07-01 Ono Pharmaceutical Co Therapeutic agent for chronic obstructive pulmonary disease
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
ATE547104T1 (en) * 2003-06-16 2012-03-15 Nycomed Gmbh COMPOSITION CONTAINING A LUNG SURFACTANT AND SILDENAFIL FOR THE TREATMENT OF LUNG DISEASES
EP1666139A4 (en) * 2003-09-10 2009-06-03 Nat Inst Of Advanced Ind Scien Oxygen scavenger and method for production thereof
AU2005268755B2 (en) * 2004-08-06 2011-04-07 Takeda Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
WO2007053800A2 (en) * 2005-10-21 2007-05-10 The Board Of Trustees Of The University Of Illinois Charge-modified lysozyme antimicrobial compositions, surfactants, and methods for infections and cystic fibrosis
MA45451A (en) * 2016-06-24 2019-05-01 Civitas Therapeutics Inc TENSIOACTIVE FORMULATIONS INTENDED FOR INHALATION
JP7419253B2 (en) * 2017-12-21 2024-01-22 キウィタス セラピューティクス，インコーポレイテッド Surfactant formulations for inhalation
EP3727353A4 (en) * 2017-12-21 2021-10-13 Civitas Therapeutics, Inc. Surfactant formulations for inhalation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816616A (en) * 1971-11-30 1974-06-11 Warner Lambert Co Unitary shampoo and cream rinse compositions
US5059414A (en) * 1988-07-01 1991-10-22 Shiseido Co. Ltd. Multi-phase high viscosity cosmetic products
EP0528034B1 (en) * 1990-05-18 1999-04-21 Tokyo Tanabe Company Limited Remedy for asthma
DE4418936A1 (en) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptide
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6180142B1 (en) * 1998-08-21 2001-01-30 The Regents Of The University Of California Reduction of surfactant inactivation in pulmonary surfactant therapy
IT1308180B1 (en) * 1999-02-12 2001-12-07 Chiesi Farma Spa SYNTHETIC PEPTIDES HAVING THE ABILITY TO DECREASE SURFACE TENSION AND THEIR USE IN THE PREPARATION OF A SURFACTANT
JP2003501481A (en) * 1999-06-11 2003-01-14 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Surfactant protein B (SP-B) variant and surfactant protein C (SP-C) variant containing pharmaceutical preparation

Also Published As

Publication number Publication date
WO2001058423A1 (en) 2001-08-16
JP2003522138A (en) 2003-07-22
EP1259222A1 (en) 2002-11-27
US20030091509A1 (en) 2003-05-15
CA2399944A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1531837A4 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
AU2001253723A1 (en) Dispersible absorbent products and methods of manufacture and use
EP1392292A4 (en) Pyranoindazoles and their use for the treatment of glaucoma
AU2001233757A1 (en) Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
FI20002114A (en) Use of recombinant enzymes for the preparation of GDP-L-fucose and fucosylated glycans
AU2001293891A1 (en) New combination for the treatment of asthma
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU2002251054A1 (en) Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases